These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 32547545)

  • 1. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N
    Front Immunol; 2020; 11():976. PubMed ID: 32547545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4
    Hart M; Nickl L; Walch-Rueckheim B; Krammes L; Rheinheimer S; Diener C; Taenzer T; Kehl T; Sester M; Lenhof HP; Keller A; Meese E
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity.
    Karin N; Razon H
    Cytokine; 2018 Sep; 109():24-28. PubMed ID: 29449068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
    Dengel LT; Norrod AG; Gregory BL; Clancy-Thompson E; Burdick MD; Strieter RM; Slingluff CL; Mullins DW
    J Immunother; 2010; 33(9):965-74. PubMed ID: 20948440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of tumour-infiltrating lymphocytes in a tumour rejection cynomolgus macaque model.
    Satooka H; Ishigaki H; Todo K; Terada K; Agata Y; Itoh Y; Ogasawara K; Hirata T
    Sci Rep; 2020 May; 10(1):8414. PubMed ID: 32439888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
    J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
    Müller M; Carter S; Hofer MJ; Campbell IL
    Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis.
    Li Q; Sun J; Cao Y; Liu B; Li L; Mohammadtursun N; Zhang H; Dong J; Wu J
    Biomed Pharmacother; 2020 Mar; 123():109735. PubMed ID: 31864210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets.
    Karin N; Wildbaum G; Thelen M
    J Leukoc Biol; 2016 Jun; 99(6):857-62. PubMed ID: 26657511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes Simplex Virus Type 2 Infection-Induced Expression of CXCR3 Ligands Promotes CD4
    Zhang M; Deng X; Guan X; Geng L; Fu M; Zhang B; Chen R; Hu H; Hu K; Zhang D; Li M; Liu Y; Gong S; Hu Q
    Front Immunol; 2018; 9():2932. PubMed ID: 30619292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and regulation of the CXCL9-11 chemokines and CXCR3 receptor in Atlantic salmon
    Valdés N; Espinoza D; Pareja-Barrueto C; Olate N; Barraza-Rojas F; Benavides-Larenas A; Cortés M; Imarai M
    Front Immunol; 2024; 15():1455457. PubMed ID: 39301034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors.
    Bronger H; Magdolen V; Goettig P; Dreyer T
    Cancer Metastasis Rev; 2019 Sep; 38(3):417-430. PubMed ID: 31482487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding.
    Cox JH; Dean RA; Roberts CR; Overall CM
    J Biol Chem; 2008 Jul; 283(28):19389-99. PubMed ID: 18411283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
    Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ
    Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the relationship between CXCR3 and its ligands and tubal tuberculosis.
    Sun H; Fan J; Shang X; Tuohetaerbaike B; Li Y; Lv J; Wang Y; Wang L; Wang J; Ma X
    Life Sci; 2021 May; 272():119047. PubMed ID: 33454369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
    Colvin RA; Campanella GS; Sun J; Luster AD
    J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
    Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
    Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome.
    Yoon KC; Park CS; You IC; Choi HJ; Lee KH; Im SK; Park HY; Pflugfelder SC
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):643-50. PubMed ID: 19850844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.
    Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE
    Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
    Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.